Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Legend Biotech Corp (LEGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Proxy Statement",
"Notice of Annual General Meeting",
"Form of Proxy",
"Voting Card and Instructions for ADS Holders"
08/15/2023 6-K Quarterly results
Docs: "6-K",
"Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights"
07/20/2023 6-K Quarterly results
06/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI ®"
05/25/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI ®"
05/18/2023 6-K Quarterly results
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech Reports First Quarter 2023 Results and Recent Highlights"
05/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings"
05/08/2023 6-K Quarterly results
04/21/2023 6-K Quarterly results
04/19/2023 6-K Quarterly results
04/18/2023 6-K Quarterly results
04/14/2023 6-K Quarterly results
04/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH 6-K",
"Legend Biotech Establishes Strategic Advisory Board"
01/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI ® Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma"
01/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K"
01/09/2023 6-K Quarterly results
01/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORP. 6-K",
"Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel in China"
12/08/2022 6-K Quarterly results
11/22/2022 6-K Quarterly results
11/21/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORP. 6-K",
"Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer"
11/04/2022 6-K Quarterly results
11/03/2022 6-K Quarterly results
10/20/2022 6-K Quarterly results
10/18/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K"
10/17/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Voting Results of 2022 Annual General Meeting"
10/03/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"EXHIBIT A"
09/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORP. 6-K",
"CARVYKTI ™ Receives Approval from Japan’s Ministry of Health, Labour and Welfare for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma"
09/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Proxy Statement",
"Notice of Annual General Meeting",
"Form of Proxy",
"Voting Card and Instructions for ADS Holders"
09/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022"
08/19/2022 6-K Quarterly results
08/05/2022 6-K Quarterly results
08/04/2022 6-K Quarterly results
07/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Underwriting Agreement",
"Opinion of Maples and Calder (Singapore) LLP",
"Legend Biotech Corporation Announces Pricing of Public Offering"
07/25/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy